A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 39
- 试验地点
- 8
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment or two prior lines of treatment if treated with KRAS inhibitor.
The drug, nuzefatide pevedotin (nuzefatide), is designed to find a specific protein called EphA2.
The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive nuzefatide, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.
详细描述
This is a Phase 2, open-label, multicenter, single-arm study to evaluate the efficacy, safety, and pharmacokinetics (PK) of nuzefatide in adult participants with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on or after one prior line of systemic therapy in the metastatic setting or on or after second line therapy with a KRAS inhibitor in the metastatic setting. Nuzefatide is a novel Bicycle® drug conjugate (BDC®) that targets EphA2, a protein often found on cancer cells, and delivers a potent anti-cancer agent (MMAE).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age at the time of signature of the informed consent form (or at least 19 years where locally defined as minimum age of consent).
- •Measurable disease as defined by RECIST v1.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or
- •Life expectancy of at least 12 weeks.
- •Histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).
- •Participants must have failed whose disease has progressed on or after only 1 prior line of therapy or on or after second line therapy with a KRAS inhibitor, with evidence of radiographic progression. Neoadjuvant or adjuvant systemic therapy may count as the first line if the participant progressed less than 6 months from the end of systemic therapy. Prior treatment with KRAS inhibitors in the first-line setting is permitted if there was no intervening treatment prior to enrollment.
- •Participants must have sufficient tumor tissue (fresh or archived) available for analysis of EphA2 tumor expression and other biomarkers.
- •Adequate organ function (hematologic, renal, and hepatic).
- •Negative pregnancy test for participants of childbearing potential (POCBP)
- •Must be willing and able to comply with the protocol and study procedures and agree to participate in the study by providing written informed consent.
排除标准
- •Chemotherapy or radiotherapy within 14 days prior to the first dose of study treatment
- •Experimental treatments within 28 days or 5 half-lives, whichever is longer, of first dose of nuzefatide study treatment
- •Prior treatment with taxane therapy (e.g., paclitaxel) for pancreatic cancer or prior treatment with any MMAE-containing agent
- •Known microsatellite instability-high (MSI-H) status and are eligible for immune checkpoint inhibitor therapy
- •Prior toxicities must have resolved to Grade 1 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0
- •Untreated central nervous system (CNS) metastases
- •Note: Additional protocol defined Inclusion/Exclusion criteria apply
研究组 & 干预措施
nuzefatide pevedotin (BT5528) Monotherapy
干预措施: nuzefatide pevedotin (BT5528) (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: Up to approximately 3 years
Percentage of participants who achieve a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the Investigator
次要结局
- Time to Progression (TTP) per RECIST v1.1(Up to approximately 3 years)
- Incidence of treatment-related adverse events (TRAEs)(Up to approximately 3 years)
- Duration of Response (DoR) per RECIST v1.1(Up to approximately 3 years)
- Overall Survival (OS)(Up to approximately 3 years)
- Disease Control Rate (DCR) per RECIST v1.1(Up to approximately 3 years)
- Progression-Free Survival (PFS) per RECIST v1.1(Up to approximately 3 years)
- Incidence of treatment-emergent adverse events (TEAEs)(Up to approximately 3 years)
- Incidence of treatment emergent serious adverse events (TESAEs)(Up to approximately 3 years)
- Incidence of laboratory abnormalities(Up to approximately 3 years)
- Clinical Benefit Rate (CBR) per RECIST v1.1(Up to approximately 3 years)
- Incidence of ECG abnormalities(Up to approximately 3 years)
- Incidence of abnormal vital signs(Up to approximately 3 years)
- Incidence of treatment modification due to adverse events(Up to approximately 3 years)